Emergent Biosolutions (EBS) Given a $68.00 Price Target at Cantor Fitzgerald

Emergent Biosolutions (NYSE:EBS) has been assigned a $68.00 price objective by Cantor Fitzgerald in a report released on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 4.62% from the company’s previous close.

A number of other equities analysts have also recently commented on EBS. Argus started coverage on Emergent Biosolutions in a report on Wednesday, June 13th. They issued a “buy” rating and a $62.00 target price for the company. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Tuesday, July 10th. Chardan Capital lifted their target price on Emergent Biosolutions from $53.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Wells Fargo & Co set a $61.00 target price on Emergent Biosolutions and gave the stock a “hold” rating in a report on Friday, August 10th. Finally, Cowen reiterated a “hold” rating and issued a $49.00 target price on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Emergent Biosolutions has an average rating of “Hold” and an average price target of $61.63.

Shares of Emergent Biosolutions stock traded up $4.68 on Tuesday, reaching $65.00. The company had a trading volume of 680,381 shares, compared to its average volume of 292,640. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 34.21, a price-to-earnings-growth ratio of 1.27 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59. Emergent Biosolutions has a 1 year low of $36.38 and a 1 year high of $65.00.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.19. The firm had revenue of $220.20 million during the quarter, compared to analysts’ expectations of $208.94 million. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company’s quarterly revenue was up 118.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 EPS. sell-side analysts predict that Emergent Biosolutions will post 2.37 earnings per share for the current fiscal year.

In related news, CEO Daniel Abdun-Nabi sold 90,776 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $60.18, for a total transaction of $5,462,899.68. Following the completion of the transaction, the chief executive officer now owns 257,343 shares in the company, valued at approximately $15,486,901.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronald Richard sold 7,893 shares of the business’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $60.02, for a total value of $473,737.86. Following the transaction, the director now owns 21,063 shares of the company’s stock, valued at approximately $1,264,201.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 165,087 shares of company stock valued at $9,597,369. 16.50% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of EBS. Summit Trail Advisors LLC boosted its holdings in Emergent Biosolutions by 4,093.4% during the 1st quarter. Summit Trail Advisors LLC now owns 1,378,959 shares of the biopharmaceutical company’s stock valued at $1,379,000 after acquiring an additional 1,346,075 shares during the period. BlackRock Inc. boosted its holdings in Emergent Biosolutions by 20.2% during the 2nd quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock valued at $271,268,000 after acquiring an additional 901,882 shares during the period. Matarin Capital Management LLC purchased a new position in Emergent Biosolutions during the 1st quarter valued at $18,524,000. Prudential Financial Inc. boosted its holdings in Emergent Biosolutions by 446.1% during the 1st quarter. Prudential Financial Inc. now owns 416,921 shares of the biopharmaceutical company’s stock valued at $21,951,000 after acquiring an additional 340,578 shares during the period. Finally, Millennium Management LLC boosted its holdings in Emergent Biosolutions by 29.6% during the 1st quarter. Millennium Management LLC now owns 917,065 shares of the biopharmaceutical company’s stock valued at $48,283,000 after acquiring an additional 209,581 shares during the period. Institutional investors own 83.01% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit